BIOCEPT, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0001 USD | +9,900.00% |
|
0.00% | -99.76% |
| 04-26 | Motion for Asset Sale Approved for Biocept, Inc. | CI |
| 04-02 | Motion for Asset Sale Approved for Biocept, Inc. | CI |
Presentation Operator MessageOperator (Operator)Good day, and welcome to the Biocept Third Qua...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Biocept, Inc. is a molecular oncology diagnostics company. The Company focuses on developing and commercializing clinical diagnostic laboratory assays designed to identify rare tumor cells and cell-free tumor deoxyribonucleic acid (DNA) from blood and cerebrospinal fluid (CSF). Its product is branded and trademarked under the name CNSide. CNSide encompasses a suite of cellular and molecular technologies intended to aid medical professionals in CSF analysis and central nervous system (CNS) disease management in patients with solid tumors. It offers and conducts its commercialized diagnostic assays, which include cell capture and enumeration, immunocytochemistry, fluorescent in situ hybridization (FISH), and next generation sequencing (NGS). It has commercialized its CNSide assays for detecting and characterizing many different carcinomas and melanoma. These assays utilize its dual cellular and ctDNA technology platforms and provide biomarker analysis from a patientâs CSF sample.
Calendar
2024-08-11
- Q2 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
0.0001
Average target price
-
| 1st Jan change | Capi. | |
|---|---|---|
| -99.76% | 262 | |
| -6.41% | 12.2B | |
| -4.07% | 8.22B | |
| +5.77% | 5.72B | |
| +28.13% | 5.42B | |
| -59.44% | 2.7B | |
| +8.04% | 2.63B | |
| -6.47% | 2.38B | |
| +21.84% | 2.1B | |
| -8.15% | 1.81B |
- Stock Market
- Equities
- BIOCQ Stock
- News Biocept, Inc.
- Transcript : Biocept, Inc., Q3 2022 Earnings Call, Nov 28, 2022
